Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung CancerSolange Peters, Tony Mok, D. Ross Camidge et al.|New England Journal of Medicine|2017Cited by 2.4k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1Giuseppe Giaccone, David H. Johnson, Roy S. Herbst et al.|Journal of Clinical Oncology|2004Cited by 1.7k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi‐Long Wu, Tony Mok, R. Linke et al.|The Lancet Oncology|2017Cited by 1.2k
Non-small-cell lung cancerCesare Gridelli, Rafael Rosell, Antônio Rossi et al.|Nature Reviews Disease Primers|2015Cited by 1.1k
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancerKirstine Jacobsen, Rafael Rosell|Nature Communications|2017Cited by 182